JOP20190219A1 - تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية - Google Patents

تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية

Info

Publication number
JOP20190219A1
JOP20190219A1 JOP/2019/0219A JOP20190219A JOP20190219A1 JO P20190219 A1 JOP20190219 A1 JO P20190219A1 JO P20190219 A JOP20190219 A JO P20190219A JO P20190219 A1 JOP20190219 A1 JO P20190219A1
Authority
JO
Jordan
Prior art keywords
receptor agonist
methods
pharmaceutical compositions
receptor antagonist
cardiovascular diseases
Prior art date
Application number
JOP/2019/0219A
Other languages
English (en)
Inventor
Ting N Lin
Jin Jean Wang
Gerald J Yakatan
Jing H Gao
Original Assignee
Cardix Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardix Therapeutics LLC filed Critical Cardix Therapeutics LLC
Publication of JOP20190219A1 publication Critical patent/JOP20190219A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

أعدت هنا تركيبة صيدلانية متضمنة اثنين أو أكثر من المركبات، حيث يكون كل مركب منهم على حدا مثبط فوسفودايستراز، مضاد مستقبل الأدينوسين، محصرات قناة الكالسيوم، ناهض مستقبل الهيستامين H1، ناهض مستقبل الهيستامين H2، مضاد مستقبل الهيستامين H3، أو ناهض مستقبل الادرينالين بيتا-?. كما أعدت هنا طريقة لعلاج أو تحسين مرض القلب والاوعية الدموية لدى شخص، تتضمن الطريقة إعطاء الشخص الذي لحاجة لذلك اثنين أو أكثر من المركبات، حيث يكون كل مركب منهم على حدا مثبط فوسفودايستراز (مثل الثيوفيللين)، مضاد مستقبل الأدينوسين (أمينوفيللين)، محصرات قناة الكالسيوم (نيفذبين)، ناهض مستقبل الهيستامين H1، ناهض مستقبل الهيستامين H2، مضاد مستقبل الهيستامين H3 (مثل بيتاهيستين أو ناتج أيضي منه) أو ناهض مستقبل الادرينالين بيتا-? (مثل ليفالبيوتيرول أو ألبيوتيرول)، حيث يتم تكوين التركيب الصيدلي على شكل جرعة للحقن أو للتناول الفموي
JOP/2019/0219A 2017-05-09 2017-06-16 تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية JOP20190219A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762503902P 2017-05-09 2017-05-09
US201862652812P 2018-04-04 2018-04-04

Publications (1)

Publication Number Publication Date
JOP20190219A1 true JOP20190219A1 (ar) 2019-09-22

Family

ID=64096944

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0219A JOP20190219A1 (ar) 2017-05-09 2017-06-16 تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية

Country Status (19)

Country Link
US (6) US11266651B2 (ar)
EP (1) EP3621593B1 (ar)
JP (1) JP6714796B2 (ar)
KR (1) KR102197429B1 (ar)
CN (1) CN109890366B (ar)
AR (1) AR113827A1 (ar)
AU (1) AU2018266106B2 (ar)
BR (1) BR112019023101B1 (ar)
CA (1) CA3038153C (ar)
CL (1) CL2019003216A1 (ar)
CO (1) CO2019010510A2 (ar)
IL (1) IL269901B (ar)
JO (1) JOP20190219A1 (ar)
MX (1) MX386873B (ar)
PE (1) PE20200741A1 (ar)
PH (1) PH12019502330A1 (ar)
RU (1) RU2715419C1 (ar)
SG (1) SG11201902949PA (ar)
WO (1) WO2018208723A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510924B2 (en) 2017-05-09 2022-11-29 CARDIX Therapeutics, LLC Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases
JOP20190219A1 (ar) * 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10582716B1 (en) * 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
KR102249155B1 (ko) * 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
CN115279346A (zh) * 2020-03-09 2022-11-01 苏什玛·保罗·伯利亚 包含屈他维林或其盐的控制释放制剂
US20220226302A1 (en) * 2021-01-20 2022-07-21 Altos Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions
CN112717092A (zh) * 2021-01-22 2021-04-30 行艳丽 一种预防心脑血管疾病的中药及制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
US12194046B2 (en) 2021-03-09 2025-01-14 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
US20250051277A1 (en) 2021-10-29 2025-02-13 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds
WO2023076547A1 (en) * 2021-10-29 2023-05-04 Sensorium Therapeutics, Inc. Deuterated forms of alkaloid compounds and therapeutic uses thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
RU2115419C1 (ru) 1997-07-09 1998-07-20 Геннадий Иванович Марков Лекарственное средство для адсорбционной терапии воспалительных заболеваний слизистых оболочек
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6277402B1 (en) 1998-06-26 2001-08-21 Delack Elaine Alice Method for treatment of multiple sclerosis and related disease states
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2715683A1 (en) * 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
WO2005051322A2 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
FR2886150B1 (fr) 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US8207188B2 (en) * 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
WO2008019106A1 (en) 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2344145A1 (en) * 2008-09-29 2011-07-20 Gilead Sciences, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
CN102631320B (zh) * 2012-04-24 2014-04-02 吉林大学珠海学院 一种盐酸倍他司汀脂质体及其制备方法
SMT202500110T1 (it) 2016-01-20 2025-05-12 Shenzhen Salubris Pharm Co Ltd Metabolita antagonista del recettore dell'angiotensina ii e composito inibitore della nep e relativo metodo di preparazione
EP3231417B1 (de) 2016-04-15 2018-12-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH Lagerungsstabile, ophthalmische zusammensetzung
JOP20190219A1 (ar) * 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية

Also Published As

Publication number Publication date
US12472186B2 (en) 2025-11-18
US11878017B2 (en) 2024-01-23
EP3621593C0 (en) 2025-07-09
US11911389B2 (en) 2024-02-27
KR20190075984A (ko) 2019-07-01
KR102197429B1 (ko) 2020-12-31
CA3038153C (en) 2022-03-29
RU2715419C1 (ru) 2020-02-28
AU2018266106A1 (en) 2019-04-11
CN109890366A (zh) 2019-06-14
BR112019023101A2 (pt) 2020-08-04
AR113827A1 (es) 2020-06-17
SG11201902949PA (en) 2019-05-30
US20190231786A1 (en) 2019-08-01
EP3621593B1 (en) 2025-07-09
US11266651B2 (en) 2022-03-08
US10758544B2 (en) 2020-09-01
JP6714796B2 (ja) 2020-07-01
EP3621593A4 (en) 2021-04-07
CN109890366B (zh) 2020-12-25
JP2019534250A (ja) 2019-11-28
BR112019023101B1 (pt) 2021-11-16
US11491159B2 (en) 2022-11-08
EP3621593A1 (en) 2020-03-18
US20240207279A1 (en) 2024-06-27
US20180325907A1 (en) 2018-11-15
PH12019502330A1 (en) 2020-09-28
CO2019010510A2 (es) 2020-01-17
CA3038153A1 (en) 2018-11-15
PE20200741A1 (es) 2020-07-24
WO2018208723A1 (en) 2018-11-15
MX386873B (es) 2025-03-19
US20200397793A1 (en) 2020-12-24
AU2018266106B2 (en) 2021-02-25
MX2019006233A (es) 2019-08-01
CL2019003216A1 (es) 2020-05-29
IL269901B (en) 2021-03-25
US20220184089A1 (en) 2022-06-16
US20230071157A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
CO2019010510A2 (es) Composiciones farmacéuticas y métodos para tratar enfermedades cardiovasculares
MX2020012967A (es) Combinacion farmaceutica que contiene activador de glucosacinasa y activador del receptor ppar, composicion, preparacion del compuesto, metodo de preparacion para el mismo y usos del mismo.
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
ZA202204284B (en) Inhibitors of raf kinases
NZ721617A (en) Heterocyclic compounds
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MX388643B (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
MX390461B (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion
MX2024015576A (es) Tratamiento para migra?as
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2024007444A (es) Inhibidores de cinasa met.
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
EP3821902A4 (en) TRADITIONAL CHINESE MEDICINAL COMPOSITION, TRADITIONAL CHINESE MEDICINAL PREPARATION, AND THE PROCESS FOR THEIR MANUFACTURE AND USE
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
MX2018002487A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona.
CL2021003497A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
EA201792676A1 (ru) Ингибиторы jak1
MX394259B (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)